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Background: Lung cancer may occur in the lung transplant popu-
lation because many patients are former smokers. Not much is
known about risk factors and outcomes in these patients.
Methods: We performed a search of the lung transplant database at
our institution to identify patients who had been diagnosed with lung
cancer. Records and reports were reviewed for demographics, risk
factors for malignancy, lung transplant characteristics, radiographic
characteristics, treatment, and outcomes.
Results: We identified 12 lung transplant patients with broncho-
genic carcinoma at our institution age 47.2  13.2 years (mean 
SD); 7 (58%) men and 5 (42%) women. Eleven patients were
transplanted for chronic obstructive pulmonary disease (COPD).
Time from transplantation to diagnosis of cancer was 119 (21–416)
mean (range) weeks. Eleven cancers occurred in the native lung;
most common cancer cell types were adenocarcinoma (N  5).
Incidence among patients with COPD, who received single lung
transplantation was 5.15%. Time from diagnosis of bronchogenic
carcinoma to death was 10.8 (1–60) mean (range) weeks with a
75% (9/12) 1-year mortality.
Conclusions: Among our patients, almost all cancers occurred in
native lung in ex-smokers who received a lung transplant for COPD.
The cancer was often an incidental finding on a routine chest
radiograph; however, the disease was usually at an advanced stage
at diagnosis, limiting therapeutic options.
Key Words: Cancer, Transplant, Bronchogenic carcinoma, Immu-
nosuppression, Lung.
(J Thorac Oncol. 2008;3: 1404–1409)
Lung transplantation (LTXP) has emerged as a viable ther-apy for patients with advanced lung diseases, including
chronic obstructive pulmonary disease (COPD). Most LTXP
recipients without suppurative lung disease receive single
lung transplants and may be at increased risk of developing
bronchogenic cancer (BCa) in the native lung. Pulmonary
nodules or masses in LTXP recipients may represent a variety
of etiologic possibilities and occur in native or transplanted
lung.1 Lung transplant recipients are also at an increased risk
of malignancy because of prolonged immunosuppression.
Previous reports suggest that BCa are the third most common
type of malignancy occurring after solid-organ transplanta-
tion with a frequency similar to that in the general popula-
tion.2 Nevertheless, limited information exists in literature
related to the occurrence of BCa in LTXP recipients. This
may be due to the small number of LTXP and short survival
posttransplant. Thus, many questions remain unanswered,
including risk factors, presenting features, and treatment
outcomes. This study was conducted to review our experi-
ence with such patients and to provide a review of the
previously reported cases in the literature in an attempt to
answer these questions.
MATERIALS AND METHODS
Records of patients between 1990 and 2006 were re-
viewed to identify those with BCa after LTXP. Pretransplant
evaluation included complete metabolic panel, cytomegalo-
virus and Epstein-Barr virus titers, pulmonary function test-
ing, chest radiograph (CXR), computed tomographic (CT)
scan of the chest, and echocardiogram. Posttransplantation
period follow up included clinical evaluation, laboratory
testing, spirometry, CXR, and surveillance bronchoscopy at 3
and 6 weeks and 3-, 6-, 9-, and 12-months. Clinical evalua-
tion, spirometry, and CXR were performed every 3 months
thereafter. A chest CT scan was obtained at the discretion of
the clinician based on symptoms or CXR findings. The
regimen and dose of immunosuppression was standard as
previously described.1
A Medline and PubMed search of the English language
literature was carried out for reported studies and cases of
BCa developing after LTXP. Criteria for exclusion from our
analysis included (1) patients transplanted for BCa who then
developed cancer or (2) those having cancer in explanted
lungs and developing the same cancer in transplanted lung
within the first year posttransplant, indicating the likelihood
that this was recurrent and not de novo cancer. This literature
was analyzed for underlying reason for LTXP, demographics,
LTXP characteristics, type of cancer, results of imaging and
diagnostic techniques, and treatment outcomes. An overall
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analysis of all cases (our experience and literature) was
performed to determine clinical characteristics, presenting
features, and treatment outcomes.
RESULTS
Between 1990 and 2006, 520 LTXP (258 M/262 F)
were performed at our institution. No patients were trans-
planted for BCa and those found to have cancer during
pretransplant evaluation or at the time of transplantation (N 4)
were excluded from this analysis. Patients underwent either
single (N  286) or double (N  234) LTXP for COPD/
emphysema (N  242), cystic fibrosis (N  90), interstitial
lung disease (N  84), and the rest (N  104) for other lung
diseases. The mean patient age at time of LTXP was 47.2 
13.2 years.
Of the 520 LTXP, 12 (2.3%) patients developed 13
BCa (Tables 1 and 2). Seven (58%) were men and 5 (42%)
were women. The mean age was 58 years with a range of 36
to 67. Eleven had COPD (one of whom also had idiopathic
hemosiderosis), and one had idiopathic pulmonary fibrosis.
Among 520 LTXP recipients, 7/258 (2.71%) men and 5/262
(1.90%) women were diagnosed with BCa. All patients were
ex-smokers with at least 30 pack-year history of smoking.
Eleven cancers occurred in native lung, whereas two occurred
in transplanted lung in the same patient. The patient who
developed recurrent BCa in transplanted lung was a 100
pack-year smoker and her donor also had 50 pack-year
smoking history. The incidence of BCa in our study was 0.75
per 100 patient-years, whereas the prevalence was 3.84%
(11/286) in those receiving single LTXP and 5.15% (10/194)
among patients with COPD who received single LTXP.
Cancer cell types included small cell carcinoma (N  2);
non-small cell (N  11) (adenocarcinoma, N 5; large cell,
N  3; squamous cell, N  3). Immunosuppression regimens
TABLE 1. Demographic Characteristics of Lung Transplant Recipients at Cleveland Clinic with Bronchogenic Carcinoma
No. Age, Gender Reason for LTXP Type of LTXP Smoking (Pack Years) Lung with Cancer AR/BOS Cell Type
1 59, M COPD RSLT 40 Native 2/N SqCC
2 56, F COPD RSLT 40 Native 1/N LCC
3 63, M COPD RSLT 90 Native 1/N SmCC
4 67, M IPF LSLT 45 Native 3/N Adeno
5 64, M COPD LSLT 45 Native 0/Y LCC
6 36, F COPD, IPH LSLT Yes Native 0/N SmCC
7 65, F COPD RSLT 30 Native 2/N LCC
8 63, M COPD RSLT 60 Native 0/N Adeno
9 55, F COPD DLT 100 Transplanted 0/Y Adeno
10 58, M COPD LSLT 40 Native 1/Y SqCC
11 65, M COPD LSLT 35 Native 2/N Adeno
12 44, F COPD (A1ATD) LSLT 50 Native 2/N SqCC
Adeno, adenocarcnoma; A1ATD, alpha-1 antitrypsin deficiency; AR, number of episodes of acute rejection; BOS, bronchiolitis obliterans syndrome; COPD, chronic obstructive
pulmonary disease; DLT, double lung transplant; IPF, idiopathic pulmonary fibrosis; IPH, idiopathic pulmonary hemosiderosis; L, left-sided; LCC, large cell cancer; LTXP, lung
transplant; R, right-sided; SLT, single lung transplant; SmCC, small cell cancer; SqCC, squamous cell cancer.
TABLE 2. Diagnostic Modalities and Treatment Outcomes in Lung Transplant Recipients at Cleveland Clinic with
Bronchogenic Carcinoma




Procedure Mets Treatment T2 (wk) Outcome
1 Back pain Multiple nodules LUL 124 PCNA Bone RT 6 Dead
2 Asymp Mass Left hilum 38 Liver biopsy Bone, liver Palliative 3 Dead
3 DOE, cough, CP Mass, effusion LLL 57 TBBX, thoracentesis None Palliative RT 4 Dead
4 DOE, cough Pleural nodules Right pleural 70 VATS None Chemo RT 10 Dead
5 DOE Mass Right hilum 63 LN biopsy Liver Palliative 5 Dead
6 Right chest pain Nodule RLL 52 PCNA Bone Palliative 8 Dead
7 Fatigue Nodule LLL 200 VATS None Lobectomy Alive 90 Alive
8 DOE, CP Infiltrate LLL 416 TBBX Bone Palliative RT 8 Dead
9 Asymp Nodule LUL, LLL 132 TBBX None Lobectomy 60 Dead
Cough, DOE 184 None Palliative RT
10 Cough Fibrotic mass RUL 129 TBBX None Right pneumonectomy 3 Dead
11 DOE Infiltrate, effusion RLL 21 Pleural biopsy None Palliative 1 Dead
12 Asymp Nodule RLL 136 BW None RT Alive 26 Alive
Asymp, asymptomatic; BW, bronchial washings; chemo, chemotherapy; CP, chest pain; CT, computed tomographic scan; CXR, chest radiograph; DOE, dyspnea on exertion;
L, left lung; LL, lower lobe; LN, lymph node; mets, metastases; PCNA, percutaneous needle aspiration; R, right lung; RT, radiation therapy; T1, time from lung transplantation to
detection of cancer; T2, time from diagnosis of cancer to death or most recent follow-up; TBBX, transbronchial biopsy; UL, upper lobe; VATS, video assisted thoraco-scopic surgery.
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used were prednisone  cyclosporine  azathioprine (N  6),
prednisone  tacrolimus  azathioprine (N  5), and pred-
nisone  tacrolimus  mycophenolate (N  1). There were
7 (58%) patients with at least one episode of acute rejection
and 5 (42%) with two or more episodes. Three patients met
the criteria for bronchiolitis obliterans and were placed on
rapamycin (N  3) and/or methotrexate (N  1).
Only three patients had no new symptoms at presentation.
All cancers were detectable by CXR and the majority occurred
in the lower lung zones N  8 (61.5%). Most recent chest
imaging (CXR or CT) retrospectively reviewed did not reveal
any “missed” detectable abnormalities that may have led to more
extensive testing and an earlier diagnosis of BCa.
Time from LTXP to the diagnosis of malignancy (T1)
was 119 (21–416) mean (range) weeks. Treatment options
were limited because five BCa had metastases at presentation
with bones being the most common site. Of the remaining
seven patients (eight BCa), four cancers were not amenable to
curative surgical intervention in view of pleural involvement
(patients 3, 4, and 11) or poor pulmonary function (patient
12). In the three patients, where the tumor was felt to be
amenable to curative surgical intervention, one (patient 7)
underwent successful left lower lobectomy and is still alive,
and the second patient (patient 9) underwent left upper
lobectomy for the first cancer and developed a second cancer
in the lower lobe of the same lung a year later. She was not
thought to be a candidate for reoperation at this time in view
of her poor pulmonary function. The third patient (patient 10)
had a history of right upper lobe bullectomy making surgery
difficult and died of respiratory failure and sepsis 2 weeks
after surgery. In those not felt to be amenable to surgery, a
uniformly poor outcome was obtained with attempts at che-
motherapy or radiation therapy (Table 2). Two patients re-
main alive to date, for the other patients; time from diagnosis
of cancer to death was 10.8 (1–60) mean (range) weeks
with a 75% (9/12) 1-year and 83% (10/12) 2-year mortality.
A search of the English language literature revealed 12
reports (Refs. 3–14) of patients who developed BCa after
LTXP. Eleven of these reports (23 individually reported BCa)
met our selection criteria. One report12 included 24 patients
from seven different LTXP centers and described only clin-
ical and radiographic findings in overall groups without
individual information identifiable to specific patients. Treat-
ment information was also not included in this report. In our
analysis, results from this report were included where possi-
ble. Data were analyzed after combining information from
our patients (12 patients and 13 BCa) with those reported in
the literature (47 patients 23 separate patients and 24 from
Ref. 13) to obtain an overview of the reported English
language literature on this subject. Tables 3 and 4 describe
salient baseline demographic characteristics, clinical features,
and treatment outcomes of overall group.
Most cancers presented within the first 2 (52%) or 3
(66%) years posttransplant. Seventy-six percent of patients
were transplanted for COPD, 83% had a history of smoking,
and only 3 (of 59) patients were known to be nonsmokers.
Almost all cancers were in the native lung, which was
exposed to the effects of smoke for many years before LTXP.
Only 4 (7%) patients developed cancer in the transplanted
lung. Of these four, one patient was ours whose donor had
history of smoking. Donor history of smoking was not re-
ported in the case of three patients reported in the literature.
Most cancers presented as nodules or masses and were
equally distributed between the upper and lower lung zones.
Nodules and masses typically had shaggy or irregular borders
and were not calcified.
Approximately 40% of patients underwent surgical inter-
vention and approximately 30% had either palliative or no
therapy in view of the extensive nature of their disease. In the
overall group, survival from diagnosis of BCa to death was
available in only 35 patients and 16/35 (46%) and 20/35 (57%)
of patients died within 3 months and 1 year of the diagnosis,
respectively. At our institution, only two patients who under-
went surgical resection for limited disease survived beyond 1
year and one of these patients developed a second BCa and died
as a result. In the cases reported in the literature, three patients
survived longer than 1 year, two had surgical intervention, and
the other had chemotherapy and radiotherapy. Of those reported
as “alive” only two patients were known to be alive after 1 year,
and duration of follow-up for others was not reported. One of
these patients developed delayed metastases to the brain and
received radiotherapy.
DISCUSSION
This series represents the largest reported single center
experience with BCa developing after LTXP and a compre-
TABLE 3. Demographic Characteristics of Lung Transplant
Recipients with Bronchogenic Carcinoma
Characteristic CC Literature Overall
N 12 patients 47 59 patients
13 cancers 60 cancers
Age (yrs)
Mean 58 58 58
Range 36–67 25–68 25–68
Gender
Male 7 (58) 22 (47) 29 (49)
Female 5 (42) 15 (32) 20 (34)
NA 0 10 (21) 10 (17)
Reason for LTXP
COPD 11 (91.6) 34 (72) 45 (76)
IPF 1 (8.3) 10 (21) 11 (19)
Other 0 2 (4) 2 (3)
NA 0 1 (2) 1 (2)
Type of LTXP
SLT 11 (91.6) 43 (91) 54 (91)
DLT 1 (8.3) 3 (6) 4 (7)
NA 0 1 (2) 1 (2)
Smoking history
Yes 12 (100) 37 (79) 49 (83)
No 0 3 (6) 3 (5)
NA 0 7 (15) 7 (12)
CC, Cleveland Clinic; COPD, chronic obstructive pulmonary disease; DLT, double
lung transplant; IPF, idiopathic pulmonary fibrosis; LTXP, lung transplant; NA, not
available; SLT, single lung transplant.
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hensive review of the literature on the subject. Our experi-
ence indicates that incidence of BCa is much higher in LTXP
than in general population, almost all BCa occur in former
smokers, most patients have nonspecific symptoms at presen-
tation, most BCa present within the first 3 years post-LTXP,
and unless amenable to surgical resection, response to ther-
apy is extremely poor. Previous reports on BCa in the LTXP
population have either been reports of isolated cases10 or have
included other organ transplant recipients,3,9 who may have
different risk factors and have included patients who were
transplanted for BCa or those who had cancer in the ex-
planted lung and developed the same cancer in the trans-
planted lung within a few months of the transplant.6,15 These
patients likely do not represent true development of BCa after
LTXP, rather manifestation of a cancer already present. By
excluding these two groups of patients, we believe that our
series and literature review truly represents patients develop-
ing BCa after LTXP.
The lifetime incidence of BCa is reportedly 0.9% in
men and 0.54% in women in the general population,16 and
BCa is the most common cause of cancer-related death in the
United States in both men and women.16–18 Though initially
thought to be infrequent,19 more recent experience indicates
that incidence of BCa in the LTXP population is 0.28 to
4.1%. Dickson et al.13 found that 6.9% of single lung trans-
plant recipients who survived more than or equal to 90 days
developed BCa. The incidence of BCa at our institution is in
line with these estimates and confirms that incidence of lung
cancer among solid-organ recipients is much higher than that
in general population.16–20 Previous reports have indicated a
higher incidence of BCa in patients with low forced expira-
tory volume in 1 second21,22 and an increasing risk of BCa
with progressively decreasing forced expiratory volume in 1
second.23 The risk of developing BCa in our population was
similar to these “high risk” groups. The mean age at presen-
tation was also younger than that in the general population.20
Recently, groups at high risk for development of lung cancer
have been identified and followed as part of CT screening
trials. These trials have reported lung cancer incidences based
on the results of CT studies performed yearly. The incidence
reported in two large US trials, the Early Lung Cancer Action
Projects24,25 and screening studies performed at the Mayo
clinic,26–28 was 0.59 and 0.62 per 100 patient-years, respec-
tively. The incidence in a large international lung cancer
screening trial was 0.27 per 100 patient-years.29 The inci-
dence in our study was 0.75 per 100 patient-years in the entire
cohort, which includes a significant proportion of younger
patients without risk for lung cancer (cystic fibrosis and
pulmonary hypertension), suggesting that our lung transplant
population should be considered as a high-risk group. The
nature of the cancers identified in the screening trials is much
different than those identified in our lung transplant group.
Overall, survival of patients identified with lung cancer in the
above international trial was reported to be 80% at 10 years.29
In another report of results from three CT screening trials 106
of 144 subjects diagnosed with lung cancer were alive after a
median follow-up of 3.9 years.30 In our group, only 2 of 12
diagnosed with lung cancer were living 2 years later.
In the overall group, risk factors for development of
cancer were similar to those seen in general population.31,32
Our review makes it clear that exposure to cigarette smoke
continues to be the single largest risk factor for BCa in these
patients despite having quit smoking years earlier. The role of
immunosuppressive therapy in development of de novo BCa
in organ-transplant recipients is a matter of debate.3,33–35
Because similar protocols for immunosuppression were used
TABLE 4. Diagnostic Modalities and Treatment Outcomes
in Lung Transplant Recipients with Bronchogenic Carcinoma
Characteristic CC Literature Overall
Type of cancer
Adeno 5 (38.4) 16 (34) 21 (35)
SqCC 3 (23) 21 (45) 24 (40)
Undiff 0 5 (11) 5 (8)
LCC 3 (23) 0 3 (5)
SmCC 2 (15.3) 2 (4) 4 (7)
Other 0 3 (6) 3 (5)
Involved lung
Native 11 (91.6) 43 (91) 54 (91)
Transplanted 1 (8.3) 3 (6) 4 (7)
NA 0 1 (2) 1 (2)
Location
Upper zone 3 (23) 13 (28) 16 (27)
Lower zone 8 (61.5) 11 (22) 19 (31)
Hilar 2 (15.3) 5 (11) 7 (12)
Other 0 5 (11) 5 (8)
NA 0 13 (28) 13 (22)
Radiographic presentation
Nodule 7 (53) 17 (37) 24 (40)
Mass 3 (23) 9 (19) 12 (20)
Infiltrate 1 (7.6) 1 (2) 2 (3)
Effusion 2 (15.3) 5 (11) 7 (12)
Other 0 4 (8) 4 (7)
NA 0 11 (23) 11 (18)
Metastases
None 8 (61.5) 17 (36) 25 (42)
Bone 3 (23) 2 (4) 5 (8)
Liver 1 (7.6) 2 (4) 3 (5)
1 sites 1 (7.6) 6 (13) 7 (12)
Diagnostic procedure
FB 5 (38.4) 10 (21) 15 (26)
PCNA 2 (15.3) 10 (21) 12 (20)
Surgery 3 (23) 11 (23) 14 (23)
Other 3 (23) 5 (11) 8 (13)
NA 0 11 (23) 11 (18)
Treatment
Surgery 3 (23) 12 (54.5) 15 (43)
Chemo  RT 1 (7.6) 5 (23) 6 (17)
RT 2 (15.3) 2 (9) 4 (11)
Palliative 7 (54) 0 7 (20)
None 0 3 (14) 3 (8.5)
Adeno, adenocarcnoma; chemo, chemotherapy; FB, flexible bronchoscopy; LCC,
large cell cancer; NA, not available; PCNA, percutaneous needle aspiration; Undiff,
undifferentiated; SmCC, small cell cancer; SqCC, squamous cell cancer; RT, radiation
therapy.
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in those who developed BCa and those who did not, it is not
clear whether immunosuppression was a significant risk fac-
tor in the development of cancer. Cancers were mostly
adenocarcinoma or squamous cell cancer. The relative distri-
bution of cell type was similar to that in the general popula-
tion except that only 6% of cancers were small cell type.
These findings may have prognostic implications in that
non-small cell cancers are less likely to be metastatic at initial
presentation compared with small cell cancers.36
Similar to the general population,37,38 only a minority
of our patients 3/13 (23%) cancers were asymptomatic;
however, symptoms were generally nonspecific. In at least
three other patients, the symptoms were not significantly
different from the patient’s baseline symptoms and “routine”
CXR led to the diagnosis. Even though there is no established
mortality benefit from screening for BCa in the general
population, we feel that this may be a feasible option in this
high-risk population. It is the recommendation of the authors,
and the practice at most LTXP centers, that all LTXP recip-
ients should receive a CXR at each visit for clinical evalua-
tion after LTXP. The inadequacy of CXR as a screening tool
has been alluded to by other authors.3,39–41 This is a concern
especially because our review indicates that most BCa occur
in the native lung. Subtle changes associated with early
malignant process may be masked by underlying lung disease
or by postsurgical changes.9,12 It is also known that CXR has
less than 50% chance of detecting a lung nodule less than 8
to 10 mm in diameter,12,42 hampering efforts at earlier detec-
tion. More aggressive screening may be a consideration,
especially in the first 3 years post-LTXP.
Diagnosis of BCa in immunosuppressed population
portends a poor prognosis. Our experience and the litera-
ture seem to indicate that those diagnosed at a stage where
curative surgical intervention can be attempted have the
best outcomes. We feel that, as in the general population,
surgical resection offers the best opportunity for cure.
Nevertheless, this may not be possible given the borderline
pulmonary function in many of these patients and their
comorbidities. Some of the patients who underwent surgi-
cal intervention subsequently developed recurrent local or
metastatic cancer. In addition, two of our patients (patients
2, 11) developed BCa early after LTXP. It is possible that
these patients may have had early BCa at the time of LTXP
not identifiable by routine pretransplant work-up, includ-
ing chest CT scanning.
In conclusion, LTXP recipients have risk factors, in-
cluding a history of smoking and prolonged immunosuppres-
sion that make them uniquely susceptible to development of
BCa. Almost all cancers occurred in the native lung and
double LTXP may be a better option in those with a history
of smoking. Even though most patients are symptomatic at
presentation, these symptoms are usually nonspecific and
BCa is often an incidental finding on routine CXR. Once
diagnosed, disease is usually at an advanced stage limiting
therapeutic options and prognosis is extremely poor. At a
minimum these patients should have CXR and clinical fol-
low-up every 3 to 4 months and radiographic changes should
be thoroughly evaluated.
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